Phase II study of Carboplatin plus nab-Paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease - Phase II study of CBDCA plus nab-PTX for advanced NSCLC patients with ILD

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Advanced non-small cell lung cancer with interstitial lung disease
Sponsor: Kanagawa Cardiovascular and Respiratory Center
Enrollment: 90
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

February 3, 2014

End Date

January 9, 2018

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\) Synchronous or metachronous active double malignancies 2\) Other lung disease, including infection, pneumoconiosis, drug\-induced pneumonitis, sarcoidosis, and collagen vasucular disease 3\) With symptomatic central nervous system metastases 4\) Hypersensitvity to platinum or paclitaxel 5\) Receiving systemic treatment with steroid or immunosuppressant 6\) Positive for hepatitis B surface antigen 7\) Women who are currently pregnant or will not be compliant with a medically approved contraceptive regimen during the treatment period and lactating women. 8\) Men who will not be compliant with a contraceptive regimen during and for the treatment period 9\) Psychotic disorder which prevent the patient from giving informed consent 10\) Other criteria judged by the investigator to make a patient unsuitable for the study